Comparing Senomyx (SNMX) and Ironwood Pharmaceuticals (IRWD)

Share on StockTwits

Senomyx (NASDAQ: SNMX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent recommendations and price targets for Senomyx and Ironwood Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senomyx 0 1 0 0 2.00
Ironwood Pharmaceuticals 1 5 3 0 2.22

Senomyx currently has a consensus price target of $2.00, indicating a potential upside of 92.31%. Ironwood Pharmaceuticals has a consensus price target of $17.29, indicating a potential upside of 20.37%. Given Senomyx’s higher possible upside, equities research analysts plainly believe Senomyx is more favorable than Ironwood Pharmaceuticals.

Profitability

This table compares Senomyx and Ironwood Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Senomyx -4.31% -9.05% -5.82%
Ironwood Pharmaceuticals -39.20% -2,073.20% -21.05%

Volatility and Risk

Senomyx has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Valuation & Earnings

This table compares Senomyx and Ironwood Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Senomyx $29.32 million 1.70 -$1.26 million ($0.03) -34.67
Ironwood Pharmaceuticals $298.28 million 7.26 -$116.93 million ($0.93) -15.44

Senomyx has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Senomyx is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

29.6% of Senomyx shares are held by institutional investors. 12.4% of Senomyx shares are held by company insiders. Comparatively, 7.6% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Senomyx beats Ironwood Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Senomyx Company Profile

Senomyx, Inc. is focused on using taste receptor technologies to discover, develop and commercialize flavor ingredients for the packaged food, beverage and ingredient supply industries. The Company operates through development and commercialization of flavor ingredients segment. It is engaged in the discovery, development and/or commercialization of flavor ingredients through over five programs. The Sweet Taste Program is focused on developing flavor ingredients or discovering natural sweeteners. The Savory Flavor Program is focused at flavor ingredients to be used in product categories, such as ready meals, sauces, soups and snack foods. The Bitter Blocker Program is focused on flavor ingredients used in products that contain bitter tastants. The Cooling Taste Program is focused at flavor ingredients used in products that consist of cooling agents. The salt taste modifier program is focused on reduction of the level of salt contained in packaged food and beverage products.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Senomyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senomyx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.